Unnatural Products Secures $45M to Advance Peptides
SANTA CRUZ, Calif., March 16, 2026 Unnatural Products has announced the successful closing of a $45 million Series B...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SANTA CRUZ, Calif., March 16, 2026 Unnatural Products has announced the successful closing of a $45 million Series B...
NEW YORK, Feb. 24, 2026 — Bristol Myers Squibb announced its participation in the upcoming TD Cowen 46th Annual...
